About SpotitEarly

SpotitEarly provides an at-home, non-invasive breath test for early cancer pre-screening. Their proprietary LUCID AI platform analyzes volatile organic compounds (VOCs) in breath samples to detect early signs of multiple cancer types, increasing accessibility and adoption of preventative healthcare.

<problem> Current cancer screening methods often require clinic visits, are invasive, and have low adoption rates, leading to late-stage diagnoses. This limits accessibility and timely intervention for many individuals. </problem> <solution> SpotitEarly offers an at-home, non-invasive breath test designed for early cancer pre-screening across multiple cancer types. The solution utilizes a simple breath sample analyzed by the proprietary LUCID AI platform, which identifies volatile organic compounds (VOCs) associated with cancer. This approach aims to significantly increase cancer screening adoption by providing an affordable, convenient, and accessible option for widespread use. The technology leverages biosensors, data science, and biochemistry to interpret complex breath signatures, offering a new layer of preventative healthcare. </solution> <features> - At-home, non-invasive breath collection kit for multiple cancer pre-screening. - Proprietary LUCID AI platform for analyzing volatile organic compounds (VOCs) in breath samples. - High accuracy demonstrated with 94% sensitivity and specificity in early-stage cancer detection. - Integration of biosensor technology with advanced data science and AI for precise biomarker identification. - Online prescription and subscription-based model for enhanced accessibility and affordability. - Designed to complement existing screening protocols as an additional pre-screening layer. - Patent pending technology (WO2023239834A1) in the field of breath analysis for disease detection. - CLIA registration number: 99D2307137. </features> <target_audience> The primary target audience includes individuals seeking convenient and accessible cancer pre-screening options, as well as healthcare providers and networks looking to expand preventative care offerings. </target_audience> <revenue_model> Revenue is generated through an online subscription model for the at-home test kits. </revenue_model>

What does SpotitEarly do?

Where is SpotitEarly located?

SpotitEarly is based in Englewood, United States.

When was SpotitEarly founded?

SpotitEarly was founded in 2020.

How much funding has SpotitEarly raised?

SpotitEarly has raised 20300000.

Location

Englewood, United States

Founded

2020

Funding

20300000

Employees

33 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

SpotitEarly

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

beta.spotitearly.com 1K+

Crunchbase

Founded 2020 – Englewood, United States

Funding

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Current cancer screening methods often require clinic visits, are invasive, and have low adoption rates, leading to late-stage diagnoses. This limits accessibility and timely intervention for many individuals.

Solution

SpotitEarly offers an at-home, non-invasive breath test designed for early cancer pre-screening across multiple cancer types. The solution utilizes a simple breath sample analyzed by the proprietary LUCID AI platform, which identifies volatile organic compounds (VOCs) associated with cancer. This approach aims to significantly increase cancer screening adoption by providing an affordable, convenient, and accessible option for widespread use. The technology leverages biosensors, data science, and biochemistry to interpret complex breath signatures, offering a new layer of preventative healthcare.

Features

At-home, non-invasive breath collection kit for multiple cancer pre-screening.

Proprietary LUCID AI platform for analyzing volatile organic compounds (VOCs) in breath samples.

High accuracy demonstrated with 94% sensitivity and specificity in early-stage cancer detection.

Integration of biosensor technology with advanced data science and AI for precise biomarker identification.

Online prescription and subscription-based model for enhanced accessibility and affordability.

Designed to complement existing screening protocols as an additional pre-screening layer.

Patent pending technology (WO2023239834A1) in the field of breath analysis for disease detection.

CLIA registration number: 99D2307137.

Target Audience

The primary target audience includes individuals seeking convenient and accessible cancer pre-screening options, as well as healthcare providers and networks looking to expand preventative care offerings.

Revenue Model

Revenue is generated through an online subscription model for the at-home test kits.